Stockreport

UroGen begins subject dosing in Phase III bladder cancer drug trial [Yahoo! Finance]

UroGen Pharma Ltd. - Ordinary Shares  (URGN) 
Last urogen pharma ltd. - ordinary shares earnings: 3/2 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.urogen.com
PDF clinical trial of its investigational drug UGN-103 (mitomycin) for an intravesical solution to treat low-grade intermediate-risk non-muscle invasive bladder cancer (LG-I [Read more]